Sign in
Not yet recruitingNo phase

Dexmedetomidine-Esketamine Combination for Sedation and Analgesia in ICU Patients

Key facts

Who runs it
Peking University First Hospital
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
1,508 people, planned
Started
Nov 2025
Expected to end
1 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Dexmedetomidine-Esketamine Combination
  • Dexmedetomidine
Record updated
31 July 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Aged ≥18 years
  • Receiving invasive or non-invasive mechanical ventilation in the ICU, with an expected duration ≥24 hours
  • Require sedation as judged by ICU physicians

Who cannot take part

  • Unable to communicate due to coma, severe dementia, or language barrier prior to invasive/non-invasive mechanical ventilation
  • History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis
  • After stroke, hypoxic encephalopathy, traumatic brain injury, or neurosurgery
  • Allergy to dexmedetomidine and/or esketamine, or any other conditions that are considered unsuitable for study participation
  • Left ventricular ejection fraction <30%, sick sinus syndrome, severe sinus bradycardia (heart rate <50 bpm), second-degree or higher atrioventricular block without a pacemaker, or systolic blood pressure <90 mmHg despite use of vasopressors
  • Pregnant or lactating women
  • Comorbid with hyperthyroidism or pheochromocytoma
  • Severe liver dysfunction (Child-Pugh Class C), severe renal dysfunction (requiring dialysis), or expected survival ≤24 hours

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients with mechanical ventilation in the intensive care unit (ICU) often develop anxiety and agitation, sleep distuebances, and delirium. Delirium occurrence is associated with worse early and long-term outcomes. Dexmedetomidine and ketamine are recommended for sedation and analgesia in ICU patients, but each may induce side effects. The sedative effects of dexmedetomidine can help mitigate the psychiatric side effects of esketamine. Recent studies showed that dexmedetomidine-esketamine combination improved analgesia and sleep quality without increasing psychiatric side effects. This trial is designed to test the hypothesis that dexmedetomidine-esketamine combination for sedation and analgesia in ICU patients with mechanical ventilation may reduce delirium and improve respiratory recovery.

The 2 groups in the trial

  • Dexmedetomidine-Esketamine CombinationTreatment being tested

    Sedation-analgesia is provided with dexmedetomidine-esketamine combination for up to 14 days or until discharge from the ICU. The formulation consists of dexmedetomidine 200 μg/2 ml and esketamine 100 mg/4 ml, diluted with normal saline to a total volume of 50 ml, resulting in a dexmedetomidine concentration of 4 μg/ml and an esketamine concentration of 2 mg/ml.

  • DexmedetomidineExisting treatment, for comparison

    Sedation-analgesia is provided with dexmedetomidine for up to 14 days or until discharge from the ICU. The formulation consists of dexmedetomidine 200 μg/2 ml, diluted with normal saline to a total volume of 50 ml, resulting in a dexmedetomidine concentration of 4 μg/ml.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Dexmedetomidine-Esketamine Combination for Sedation and Analgesia on Delirium in ICU Patients With Mechanical Ventilation: A Multicenter Randomized Trial
Record updated
31 July 2025